Investment Rating - The investment rating for the company is "Buy" [2]. Core Insights - The company, Nanwei Technology, is a leader in high-performance nano-microsphere materials, with significant improvements in its performance margins. The company has faced growth pressures due to external macroeconomic changes since 2023, but has shown notable recovery since Q4 2024, achieving a quarterly revenue of 233 million yuan, a year-on-year increase of 71.47%, and a net profit of 41 million yuan, up 38.05% [4][33]. - The company is positioned to capitalize on two major opportunities in its chromatography filler business: import substitution and commercialization expansion. The global chromatography medium market is expected to grow from 6.9 billion USD in 2023 to 9 billion USD by 2026, with a compound annual growth rate (CAGR) of 9.26%. In China, the market is projected to grow from 11.2 billion yuan in 2023 to 20.3 billion yuan by 2026, with a CAGR of 21.92% [5][18]. - The company has established a comprehensive layout in the upstream and downstream of the industry chain, enhancing its growth potential. Through a combination of self-built and acquired subsidiaries, it has expanded into chromatography instruments, consumables, protein purification systems, and in vitro diagnostic consumables [7][20]. Summary by Sections Company Overview - Nanwei Technology, founded in 2007, specializes in the research, production, and sales of high-performance nano-microsphere materials, serving various sectors including biomedicine, flat panel displays, analytical testing, and in vitro diagnostics. The company aims to become a global leader in microsphere technology [4][21]. Chromatography Filler Business - The chromatography filler and chromatography medium are critical consumables for biopharmaceutical separation and purification. The company is well-positioned to benefit from the ongoing import substitution and commercialization expansion in this sector [5][18]. - The company has developed a full range of chromatography fillers and media, making it a key player in the domestic market, which has historically been dominated by foreign brands [5][18]. Financial Projections - Revenue projections for the company from 2025 to 2027 are 1.00 billion yuan, 1.24 billion yuan, and 1.55 billion yuan, respectively. Corresponding net profits are expected to be 141 million yuan, 221 million yuan, and 285 million yuan, with earnings per share (EPS) of 0.35 yuan, 0.55 yuan, and 0.71 yuan [8][10]. Subsidiary Overview - The company has several key subsidiaries, including: 1. Fuli Instruments, a leading domestic chromatography instrument manufacturer [11]. 2. NAP Analysis, focusing on high-quality laboratory chromatography consumables [11]. 3. Saip Instrument, specializing in precision purification equipment for biopharmaceuticals [11][20]. Market Opportunities - The company is expected to benefit from the increasing domestic demand for chromatography fillers and media, driven by the growth of the biopharmaceutical industry and the trend towards import substitution [5][18].

证券代码：688690 证券简称：纳微科技 公告编号：2025-021 苏州纳微科技股份有限公司2024年年度 权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否涉及差异化分红送转：是 ? 每股分配比例 每股现金红利0.063元（含税） ? 相关日期 股权登记日 除权（息）日 现金红利发放日 一、 通过分配方案的股东会届次和日期 本次利润分配方案经苏州纳微科技股份有限公司（以下简称"公司"）2025 年 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东， 公司回购专用账户除外。 根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等有关规定，公司回购的股份不享有股东大会表决权、利润分 配、公积金转增股本、认购新股和配股等权利。 （2）本次差异化分红除权除息计算依据 公司根据上海证券交易所的相关规定，按照以下公式计算除权除息开盘参考 价： 除权（ ...

中信证券股份有限公司 关于苏州纳微科技股份有限公司差异化分红事项的 核查意见 中信证券股份有限公司（以下简称"保荐人"）作为苏州纳微科技股份有限 公司（以下简称"公司"）首次公开发行股票并在科创板上市、向特定对象发行 股票项目的保荐人，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上海证券交易所上市公司 自律监管指南第 2 号——业务办理》及《上海证券交易所上市公司自律监管指引 第 7 号——回购股份》（以下简称"《回购股份指引》"）等有关规定，对公司 2024 年度利润分配所涉及的差异化分红（以下简称"本次差异化分红"）进行了审慎 核查，具体情况如下： 一、本次差异化分红的原因 公司于 2024 年 1 月 29 日召开第二届董事会第三十一次会议，审议通过了 《关于以集中竞价交易方式回购公司股份的议案》，同意公司通过上海证券交易 所股票交易系统以集中竞价交易方式回购公司已发行的人民币普通股（A 股）股 票，用于员工持股计划或股权激励。截至 2025 年 4 月 23 日，公司总股本为 403,814,765 股，回购专用证券账户中股份数 3, ...

证券代码：688690 证券简称：纳微科技 公告编号：2025-021 苏州纳微科技股份有限公司2024年年度 权益分派实施公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/12 | 2025/6/13 | 2025/6/13 | 一、 通过分配方案的股东会届次和日期 本次利润分配方案经苏州纳微科技股份有限公司（以下简称"公司"）2025 年 5 月 15 日的2024年年度股东大会审议通过。 二、 分配方案 1. 发放年度：2024年年度 配、公积金转增股本、认购新股和配股等权利。 3. 差异化分红送转方案： （1）差异化分红方案 根据公司 2024 年年度股东大会审议通过的《关于公司 2024 年度利润分配方 案的议案》，公司拟以实施权益分派股权登记日登记的总股本扣减公司回购专用证 券账户中股份为基数，向全体股东每 10 股派发现金红利 0.63 元（含税）。公司不 进行资本公积金转增股 ...

Core Insights - The total margin financing balance on the STAR Market decreased by 66.25 million yuan compared to the previous trading day, with a total balance of 152.028 billion yuan as of May 27 [1][2] Financing Balance Summary - The highest financing balance on the STAR Market is held by SMIC, with a latest balance of 7.317 billion yuan, followed by Cambrian and Haiguang Information with balances of 4.348 billion yuan and 3.240 billion yuan respectively [1] - A total of 280 stocks saw an increase in financing balance, while 303 stocks experienced a decrease [1] - The stocks with the largest increase in financing balance include Aikasebo (52.57%), Kejie Intelligent (38.44%), and Wandesi (17.02%), while the largest decreases were seen in Jingpin Special Equipment (-23.58%), Weide Information (-18.44%), and Liyang Chip (-18.08%) [1] Securities Lending Balance Summary - The highest securities lending balance is also held by SMIC, with a latest balance of 2.5 million yuan, followed by Haiguang Information and Cambrian with balances of 1.9 million yuan and 1.6 million yuan respectively [2] - A total of 123 stocks saw an increase in securities lending balance, while 142 stocks experienced a decrease [2] - The stocks with the largest increase in securities lending balance include Yaokang Biological (424.49%), Lianying Laser (407.58%), and Nami Technology (49.43%), while the largest decreases were seen in Haiyou New Materials (-71.28%), Fangbang Co. (-66.42%), and Zhenhua New Materials (-43.34%) [2]

Investment Rating - The report does not explicitly state an investment rating for the experimental-grade silica gel matrix chromatography filler industry Core Insights - The report focuses on the experimental-grade silica gel matrix chromatography filler industry, highlighting the significant growth potential driven by the rapid development of the peptide active pharmaceutical ingredient market and the increasing demand for chromatographic materials in the pharmaceutical sector [4][22] - Key factors driving market growth include technological innovation and the trend towards domestic production, with the domestic production rate expected to rise from approximately 40% to 60% by 2030 [4][13] Industry Overview - The experimental-grade silica gel matrix chromatography filler is primarily used for laboratory analysis of organic compounds, natural products, and peptides, with applications in pharmaceutical quality analysis, food safety testing, environmental monitoring, and chemical research [5][22] - The industry is characterized by a low domestic replacement rate but a rapid pace of domestic production development, with significant contributions from both international and domestic companies [9][13] Market Dynamics - The upstream market is dominated by international chemical companies, while the midstream filler preparation market is led by overseas firms, with a current domestic production rate of about 40% [21][29] - The downstream applications are diverse, with the pharmaceutical industry being the primary demand driver, particularly due to the growth in the peptide drug market [22][32] Competitive Landscape - The market is currently fragmented, with major international players like GE, Agilent, and Waters holding significant market shares, while domestic companies are still developing their presence [40][41] - The report indicates a trend towards market concentration as domestic firms innovate and respond to cost control demands from pharmaceutical companies [43] Market Size and Growth Forecast - The global market for experimental-grade silica gel matrix chromatography fillers is projected to grow from approximately 2.15 billion yuan in 2024 to 2.81 billion yuan by 2030, with a compound annual growth rate (CAGR) of 4.5% [33][36] - The Chinese market is expected to expand from around 500 million yuan in 2024 to 900 million yuan by 2030, reflecting a CAGR of 10.3% [33][36] Policy Environment - The report outlines several supportive policies aimed at promoting the development of high-end chromatography technologies and materials, which are expected to further stimulate market growth [38][39]

Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shanghai) Law Firm confirms that the shareholder meeting of Suzhou Nawei Technology Co., Ltd. was convened and conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the meeting and its resolutions [2][12]. Group 1: Meeting Procedures - The shareholder meeting was convened based on the resolution of the company's third board meeting and followed the notification and announcement procedures as required [3][4]. - The meeting combined on-site voting and online voting, held on May 15, 2025, at the company's research center in Suzhou [4][5]. Group 2: Attendance and Qualifications - A total of 158 shareholders and authorized agents attended the meeting, holding 211,614,053 shares, which is 52.8047% of the total shares [4][5]. - The meeting was attended by 17 shareholders in person, holding 190,774,291 shares (47.6045%), while 141 shareholders participated via online voting, holding 20,839,762 shares (5.2002%) [5][6]. Group 3: Voting Procedures and Results - The meeting approved several proposals, including the 2024 annual report, financial reports, and profit distribution plan, with approval rates ranging from 98.9499% to 99.5717% [6][7][8]. - Specific proposals related to related party transactions required abstention from certain shareholders, and all resolutions were passed with significant majorities [10][11][12].

北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2024 年年度股东大会 法律意见书 二〇二五年五月 北京 • 上海 • 深圳 • 广州 • 武汉 • 成都 • 重庆 • 青岛 • 杭州 • 南京 • 海口 • 东京 • 香港 • 伦敦 • 纽约 • 洛杉矶 • 旧金山 • 阿拉木图 Beijing • Shanghai • Shenzhen • Guangzhou • Wuhan • Chengdu • Chongqing • Qingdao • Hangzhou • Nanjing • Haikou • Tokyo • Hong Kong • London • New York • Los Angeles • San Francisco • Almaty 法律意见书 北京市中伦（上海）律师事务所 关于苏州纳微科技股份有限公司 2024 年年度股东大会 法律意见书 致苏州纳微科技股份有限公司： 北京市中伦（上海）律师事务所（以下简称"本所"）作为苏州纳微科技股 份有限公司（以下简称"公司"）的法律顾问，受公司委托，指派律师出席公司 2024 年年度股东大会（以下简称"本次股东大会"）。本所律师根 ...

苏州纳微科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 15 日 证券代码：688690 证券简称：纳微科技 公告编号：2025-020 （二） 股东大会召开的地点：江苏省苏州市工业园区百川街 2 号研发中心大楼 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 158 | | --- | --- | | 普通股股东人数 | 158 | | 2、出席会议的股东所持有的表决权数量 | 211,614,053 | | 普通股股东所持有表决权数量 | 211,614,053 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 52.8047 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 52.8047 | （ ...

中信证券股份有限公司关于 苏州纳微科技股份有限公司持续督导 保荐总结报告书 保荐人编号：Z20374000 申报时间：2025 年 5 月 一、发行人基本情况 | 项目 | 内容 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 发行人名称 | 苏州纳微科技股份有限公司 | | | | | | | | 注册资本 | 万元 40,381.4765 | | | | | | | | 法定代表人 | BIWANG JACK JIANG（江必旺） | | | | | | | | 本次证券发行类型 | 首次公开发行股票并在科创板上市、向特定对象发行股票 | | | | | | | | 本次证券发行时间 | 2021 年 6 月 11 日、2022 年 5 月 | | | | | 10 | 日 | | 本次证券上市时间 | 2021 年 6 月 23 日、2022 年 7 月 | | | | | 12 | 日 | | 本次证券上市地点 | 上海证券交易所 | | | | | | | | 年度报告披露时间 | 2021 年年度报告于 2022 ...